This video examines chemotherapy options for HER2-positive breast cancer in the adjuvant setting, and what evidence there is for alternatives to an anthracycline backbone.
In this video, Sara M. Tolaney, MD, MPH, of the Dana-Farber Cancer Institute in Boston, discusses chemotherapy options for HER2-positive breast cancer in the adjuvant setting.
Most pivotal adjuvant studies have used anthracyclines as a backbone, but this form of chemotherapy is associated with higher cardiac toxicity, among others.
Here Tolaney examines one study that used an alternative regimen (docetaxel, carboplatin, and trastuzumab, or TCH) and looks ahead at the potential for new biologic agents to change the treatment approach in these patients.
